Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “Ono”) received on July 9, 2021 the results of the initial assessment of its compliance with the listing standards of the new market segments to be introduced on April 4, 2022 from the Tokyo Stock Exchange, Inc. (TSE), and confirmed its compliance with the listing standards for the “Prime Market”.

　Based on these results, at the Board of Directors Meeting held today, Ono resolved to apply to the TSE for the selection of the new market segment “Prime Market”.

　Going forward, Ono will proceed with the application process, in accordance with the schedule set by the TSE.